Study of anti-inflammatory activity and acute toxicity indicators of new silver salt of pyrazole-3-carboxamide
- Authors: Rudakova I.P.1, Novikova V.V.1, Bobrovskaya O.V.1, Gein V.L.1
-
Affiliations:
- Perm State Pharmaceutical Academy
- Issue: Vol 41, No 5 (2024)
- Pages: 138-146
- Section: Biology and experimental medicine
- Submitted: 08.07.2024
- Published: 13.11.2024
- URL: https://permmedjournal.ru/PMJ/article/view/634062
- DOI: https://doi.org/10.17816/pmj415138-146
- ID: 634062
Cite item
Abstract
Objective. To study the anti-inflammatory activity and some toxicological indicators of the new derivative of pyrazole-3-carboxamide SSP.
Materials and methods. To assess the biological activity of the compound, its anti-inflammatory effect was studied in the model of acute inflammatory edema caused by sub-plantar injection of carrageenan solution into a rat`s hind leg. The duration effect was assessed by the intensity of suppression of the inflammatory response in relation to the control level. In order to study the safety of the substance, the local irritant effect was determined when applied cutaneously in the experiments on rats. The severity of the irritant effect was assessed by the erythema degree, the amount of edema and the increase in local skin temperature. In addition, acute toxicity of the substance under study was determined. The test compound and reference drugs were applied to the skin.
Results. The study of acute toxicity of the compound SSP and the reference drug nystatin when applied cutaneously to rats showed that LD50 of both substances was more than 2500,0 mg/kg. Indicators of the degree of local irritating effect of the drugs demonstrate its absence. At the same time, the studied SSP compound has no anti-inflammatory effect administered either orally or cutaneously.
Conclusions. The data obtained allow us to classify the new silver salt of pyrazol-3-carboxamide SSP as a class 5 non-toxic substance. The studied SSP compound has no local irritant effect and does not demonstrate anti-inflammatory activity in the carrageenan inflammation model.
Full Text
Introduction
Superficial mycoses that are caused by dermatophytes and also yeast fungi are an important public health problem affecting different age groups of the population [1–4]. Topical agents are more often used for the treatment of this pathology. They are the most popular on the pharmaceutical market and account for more than 90 % of sales of all antimycotics [5].
In this regard, the search for new compounds with antifungal activity, which can potentially be used for topical therapy of mycoses, is an actual direction of pharmacy. The fact that the substance has additional pharmacological effects, such as anti-inflammatory activity, may contribute to the acceleration of the recovery process during this pathology.
The most important characteristic of the supposed pharmaceutical substance is the absence of negative effects on the human body, which is reflected by such indicators as acute toxicity, irritant effect.
The aim of the study is to investigate the anti-inflammatory activity and some toxicological indicators of a new pyrazole-3-carboxamide derivative SSP.
Materials and methods
The biological activity of a new silver salt of pyrazole-3-carboxamide, SSP was evaluated. It showed high antifungal activity in planktonic culture (pMIC501.0 mg/L, pMIC90 15.6 mg/L) and biofilm (sMIC50 11.8 mg/L) [6]. The studies were conducted in experiments on animals obtained from the nursery “Andreevka”, Moscow region. The animals were kept in compliance with the rules of laboratory practice (GLP) and the Order of the Ministry of Health of the Russian Federation No. 199n dated 01.04.2016 “Rules of Good Laboratory Practice”, as well as the terms of the guidelines for conducting preclinical studies of pharmaceuticals [7]. The conducted studies were approved by the Bioethics Commission of the Federal State Budgetary Educational Institution of Higher Professional Education PGFA of the Ministry of Health of the Russian Federation (protocol No. 7 of 20.01.2023).
Indomethacin ointment for external use produced by BIOSINTEZ PJSC (Russia), nimesulide produced by Ozon LLC (Russia) and nystatin produced by BIOSINTEZ PJSC (Russia) were used as reference pharmaceuticals.
Determination of acute toxicity of the compound at the dermal application was realized according to the guideline Р 1.2.3156-13 “Assessment of toxicity and danger of chemical substances and their mixtures for human health ”. The study included experiments on rodents (rats). Animals were randomly divided into groups by randomization. The absence of external signs of disease and homogeneity of groups by body weight (± 10 %) were considered as criteria for acceptable randomization.
The experimental medication in the suspension form in dimethyl sulfoxide and the comparison medication were applied on the skin in the back area using a dispenser in increasing doses according to Litchfield-Wilcoxon method. The fur of the animals was removed at the site of application 24 h before the beginning of the experiment. Control animals were dosed with diluent, which was dimethyl sulfoxide. Dosing was carried out according to the total mass of the sample. Groups of five animals of the same sex were used for the study of each medication dose. Besides, there were similarly sized groups of control animals, which were applied to comparison medications in the same way in an amount equivalent to the maximum tested dose of the medication.
The animals were observed for 14 days from the beginning of the experiment. Mortality, time of animal death, symptoms of poisoning, daily observation of general condition and behavior, weighing, evaluation of feed and water consumption were recorded. The dead animals were autopsied and macroscopically examined. All intoxicated animals were euthanized in a CO2 chamber and autopsied after 14 days. Macroscopic description and determination of mass ratios of internal organs and histologic studies were conducted.
Anti-inflammatory activity was determined on non-linear white rats weighing 180–250 g, both sexes, sexually mature – on the model of acute inflammatory edema caused by subplantar injection of 0.1 ml of 1 % aqueous solution of carragenin into the back paw of the rat at different routes of injection into the body [7]. The studied compound in the form of a suspension in dimethyl sulfoxide in the amount of 0.5 ml was applied on the skin of the foot of rats of the first group 1 h before injection of the phlogogenic agent. The second group of animals was injected orally at a dose of 50 mg/kg 1 h before carrageenan injection.
Animals that did not receive the medication served as a control. The increase in foot volume, indicating the development of edema, was evaluated oncometrically after 3 h after injection of the phlogogenic agent, which means at the peak of edema formation. The anti-inflammatory effect was evaluated by the expression of inhibition of the inflammatory reaction in relation to the control level. If this indicator was more than 30 %, the result was considered as positive.
The local irritant effect of the medication was studied in experiments on non-linear white rats weighing 180–210 g, of both sexes, sexually mature – by dermal application. The studied substance was placed in an amount of 0.5 g in the form of a paste on a previously depilated skin area of about 6 cm2. These skin areas were covered with gauze attached with a plaster. The exposure period lasted 4 h, after which the substance was removed. The evaluation of the irritant effect was conducted for 14 days. The expression of irritant effect was evaluated by the degree of erythema, the amount of edema (thickness of the skin fold at the application site) and the increase of local skin temperature. The degree of erythema was evaluated using colorimetric rulers of S.V. Suvorov in points. Skin fold thickness was measured using a thickness gauge TR-1–10 in millimeters. Skin temperature was measured using an electrothermometer. Animals, to which the comparison medication was applied in the same way, were used as control.
Statistical analysis of the results was conducted using the following program package Statistica 8.0. The results were analyzed by variation statistics using the Fisher-Student method [8].
Results and discussion
Evaluation of the acute toxicity of the compound SSP and the comparison medication nystatin by dermal application on rats showed that the LD50 of both substances was more than 2500.0 mg/kg. The obtained data indicate that sex differences in the acute toxicity indices of the two substances do not appear. There were no lethal effects when applied it on the skin. The use of the compared compounds in doses higher than 2500.0 mg/kg was practically impossible.
Thus, the compound SSP and the comparison medication nystatin are practically equivalent (equitoxic) in terms of acute toxicity. The clinical picture of intoxication at their single use in maximum possible amounts is characterized by the absence of signs of toxic effect, changes in the general condition and behavior of animals. Species and sex differences were not observed in the course of intoxication. The clinical picture of intoxication, caused by both compared medications, is the same.
The results of body weight measurements of the animals that experienced intoxication when the medications were applied topically at maximum doses are presented in Table 1.
Table 1. Effect of the compared medications on body weight (g) of rats after a single dermal application, M ± m
Observation time | Experimental group and sex | |||||
“Control” | “SSP” | “Nystatin” | ||||
male | female | male | female | male | female | |
Background | 176.9 ± 4.0 | 175.8 ± 1.9 | 171.6 ± 3.6 | 177.0 ± 2.7 | 173.9 ± 3.4 | 179.2 ± 3.4 |
2nd day | 179.9 ± 3.3 | 179.4 ± 3.0 | 173.3 ± 3.2 | 172.9 ± 3.1 | 168.6 ± 3.7 | 176.1 ± 3.5 |
7th day | 187.1 ± 4.2 | 188.2 ± 3.2 | 189.3 ± 5.4 | 186.6 ± 3.3 | 183.6 ± 4.7 | 187.4 ± 2.8 |
14th day | 193.9 ± 4.4 | 199.6 ± 3.6 | 193.4 ± 5.2 | 195.5 ± 2.8 | 191.7 ± 3.4 | 196.5 ± 2.7 |
Dynamics of body weight of experimental animals in all groups does not significantly differ from control data. There are no statistically significant deviations in body weight of animals in the groups receiving the compared medications.
All animals that survived intoxication, as well as animals of the control group, were euthanized in a CO2 chamber at the end of the study. External examination of rats that were killed after 14 days from the beginning of the experiment, did not reveal any significant differences between the experimental animals and the control animals. All rats are of standard proportions, with average weight. Fur is shiny, clean looking, there are no bald areas. There is no discharge from natural orifices. Visible mucous membranes are pale, shiny, smooth. According to the data of autopsy and macroscopic examination dermal application of the compared preparations in the studied doses to rats of both sexes does not cause visible changes of internal organs, including endocrine glands, gastric and intestinal mucous membranes, as well as the brain.It was found in the course of histologic study that the skin and soft tissue material of laboratory animals showed focal epidermal sloughing foci with keratin, which is a result of mechanical impact in the framework of the experiment. Inflammatory cell infiltration in the underlying dermis in areas of epidermal sloughing is not detected in all examined samples. Single perivascular dermal mononuclear cells are normal unchanged elements of skin-associated lymphoid tissue (SALT-structures). Dystrophic, alterative and inflammatory changes were not revealed in the liver and kidneys of laboratory animals. Focal disorders of blood circulation in the form of full blood of capillaries of kidneys, liver are expressions of blood redistribution in the agonal period. The obtained data allow to refer to the compound SSP to the 5th class of practically non-toxic substances (GOST 32419-2022 “International Standard. Hazard classification of chemical products. General requirements").
The results of the anti-inflammatory activity of the compound are presented in Tables 2 and 3.
Тable 2. Anti-inflammatory activity of the silver salt of pyrazole-3-carboxamide
by dermal application, M ± m
Compound | Volume gain of the foot after 3 h, % | Inhibition of reaction after 3 h, % |
SSP suspension | 94.32 ± 7.48, р = 0.220, р' = 0.005 | 10.0 |
“Indomethacin” ointment | 13.7 ± 1.7, р = 0.001 | 86.9 |
Control group | 104.8 ± 12.1 |
|
Note: p – level of statistical significance in comparison with control data; p' – level of statistical significance in comparison with “Indomethacin” ointment.
Тable 3. Anti-inflammatory activity of the silver salt of pyrazole-3-carboxamide during oral injection, M ± m
Compound | Volume gain of the foot after 3 h, % | Inhibition of reaction after 3 h, % |
SSP | 103.1 ± 9.9, р = 0.845, р' = 0.001 | 1.65 |
Nimesulide | 39.2 ± 2.9, р = 0.001 | 62.59 |
Control group | 104.8 ± 12.1 |
|
Note: p – level of statistical significance in comparison with control data; p' – level of statistical significance in comparison with nimesulide.
The injection of phlogogenic agent into animals causes a significant increase in foot volume by the third hour of observation, the increase reaches 104.8 %, this index was taken as a control value. The use of such a medication as “Indomethacin” ointment showed that the increase in carrageenan edema statistically significantly decreased, compared to control data, to 13.7 %, that is, the inhibition of the inflammatory response reaches 86.9 %. It is successfully used in practical medicine as an anti-inflammatory agent. Pre-application of the studied compound on the skin of the foot of rats causes inhibition of the inflammatory response, as compared to the control data, only by 10 %, which is not a statistically significant result (p > 0.05).
It was found that under the action of the comparison compound nimesulide the growth of carrageenan edema was statistically significantly inhibited compared to the control data. The increase of the foot volume in rats is 39.2 % (p < 0.001), i.e. inhibition of the reaction reaches 62.59 %. At the same time the studied compound SSP does not show anti-inflammatory activity, the increase of inflammatory edema by the third hour of the experiment goes with the same intensity as in the control experiments.
In the process of studying the biological activity of SSP compound, the study of local irritant effect of the compound had a special importance. It was evaluated by the degree of erythema, the amount of edema (thickness of the skin fold at the application site) and the increase in local skin temperature. The results of the study are presented in Tables 4–6.
Table 4. Skin fold thickness in rats after dermal application, M ± m
Group | Thickness of skin fold in the area of medication injection, mm | ||||
Study terms, days | |||||
Control | 1st | 3rd | 5th | 14th | |
“SSP” | 3.3 ± 0.2 | 3.4 ± 0.2 | 3.5 ± 0.3 | 3.5 ± 0.4 | 3.4 ± 0.2 |
“Nystatin” | 3.4 ± 0.3 | 3.5 ± 0.3 | 3.6 ± 0.2 | 3.6 ± 0.3 | 3.4 ± 0.3 |
Table 5. Surface skin temperature in rats after dermal application, M ± m
Group | Surface temperature t, ºC | ||||
Study terms, days | |||||
Control | 1st | 3rd | 5th | 14th | |
“SSP” | 37.6 ± 0.5 | 37.8 ± 0.5 | 37.7 ± 0.4 | 37.7 ± 0.6 | 37.7 ± 0.4 |
“Nystatin” | 37.5 ± 0.3 | 37.5 ± 0.4 | 37.6 ± 0.3 | 37.8 ± 0.3 | 37.5 ± 0.3 |
Table 6. Severity of skin erythema in rats after dermal application
Group | Level of erythema in points | ||||
Study terms, days | |||||
Control | 1st | 3rd | 5th | 14th | |
“SSP” | 0 | 1 | 0 | 0 | 0 |
“Nystatin” | 0 | 0 | 0 | 0 | 0 |
There is no increase in the thickness of skin folds during the dermal application of SSP and nystatin. Thus, it is established that the medications do not cause the development of edema.
The temperature of the skin areas at the application site did not increase when applying the SSP compound and nystatin. There were no statistically significant differences between the parameters and control data (at p < 0.05).
Analysis of the level of erythema showed that, in general, with both nystatin and the SSP compound, it was rated as zero, i.e., absent.
Conclusions
- The obtained data allow to assign the new silver salt of pyrazole-3-carboxamide SSP to the 5th class of practically non-toxic compounds.
- The compound SSP does not show local irritating effect.
- The studied silver salt of pyrazole pyrazole-3-carboxamide does not show anti-inflammatory activity on the model of carrageenan inflammation.
About the authors
Irina P. Rudakova
Perm State Pharmaceutical Academy
Author for correspondence.
Email: rudakova.i@list.ru
ORCID iD: 0000-0003-2227-8313
DSc (Medicine), Associate Professor, Head of the Department of Physiology
Russian Federation, PermV. V. Novikova
Perm State Pharmaceutical Academy
Email: rudakova.i@list.ru
ORCID iD: 0000-0003-4475-4421
DSc (Pharmacy), Associate Professor, Head of the Department of Microbiology
Russian Federation, PermO. V. Bobrovskaya
Perm State Pharmaceutical Academy
Email: rudakova.i@list.ru
ORCID iD: 0000-0002-3394-9031
DSc (Pharmacy), Associate Professor, Professor of the Department of Pharmaceutical Chemistry
Russian Federation, PermV. L. Gein
Perm State Pharmaceutical Academy
Email: rudakova.i@list.ru
ORCID iD: 0000-0002-8512-0399
DSc (Chemistry), Professor, Head of the Department of General and Organic Chemistry
Russian Federation, PermReferences
- Новикова В.В., Кучевасова М.В. Эпидемиологические особенности микозов волосистой части головы в Пермском крае. Сибирское медицинское обозрение 2023; 1 (143): 46–51 / Novikova V.V., Kuchevasova M.V. Epidemiologicheskie osobennosti mikozov volosistoj chasti golovy v Permskom krae. Sibirskoe medicinskoe obozrenie 2023; 1 (143): 46–51 (in Russian).
- Белоусова Т.А., Каиль-Горячкина М.В. Дерматофитии стоп: проблемы коморбидности и персонализированный выбор терапии. Consilium Medicum. Дерматология (Прил.) 2019; 1: 27–31 / Belousova T.A., Kail'-Goryachkina M.V. Dermatofitii stop: problemy komorbidnosti i personalizirovannyj vybor terapii. Consilium Medicum. Dermatologiya (Pril.) 2019; 1: 27–31 (in Russian).
- Pal M., Dave P., Dave K., Gutama K.P., Thangavely L., Paula C.R. et al. Etiology, clinical spectrum, epidemiology, new developments in diagnosis and therapeutic management of onychomycosis: an update. Am. J. Microbiol. Res. 2023; 11 (1): 19–24.
- Набиева Д.Д., Абдуллаев М.И. Кожные проявления и клинико-лабораторные особенности у ВИЧ-инфицированных детей. Original medicine 2023; 1: 77–84 / Nabieva D.D., Abdullaev M.I. Kozhnye proyavleniya i kliniko-laboratornye osobennosti u VICH-inficirovannyh detej. Original medicine 2023; 1: 77–84 (in Russian).
- Егорова Е.А., Шейхмамбетова Л.Р., Бекирова Э.Ю. Маркетинговый анализ ассортимента противогрибковых препаратов для местного применения на фармацевтическом рынке Российской Федерации. Современная организация лекарственного обеспечения 2021; 8 (1): 7–13 / Egorova E.A., Shejhmambetova L.R., Bekirova E.Yu. Marketingovyj analiz assortimenta protivogribkovyh preparatov dlya mestnogo primeneniya na farmacevticheskom rynke Rossijskoj Federacii. Sovremennaya organizaciya lekarstvennogo obespecheniya 2021; 8 (1): 7–13 (in Russian).
- Новикова В.В., Бобровская О.В., Гейн В.Л. Противогрибковая активность серебряных солей пирроло[3,4-с] пиразол-3-онов и пиразол-3-карбоксамидов, содержащих сульфамидную группу. Химико-фармацевтический журнал 2023; 57 (8): 41–45 / Novikova V.V., Bobrovskaya O.V., Gejn V.L. Protivogribkovaya aktivnost' serebryanyh solej pirrolo[3,4-s] pirazol-3-onov i pirazol-3-karboksamidov, soderzhashchih sul'famidnuyu gruppu. Himiko-farmacevticheskij zhurnal 2023; 57 (8): 41–45 (in Russian).
- Руководство по проведению доклинических исследований лекарственных средств. Под ред. А.Н. Миронова. М.: Гриф и К 2012; 944 / Guidelines for conducting preclinical studies of medicinal products. Pod red. A.N. Mironova. Moscow: Grif i K 2012; 944 (in Russian).
- Прозоровский В.Б. Статистическая обработка результатов фармакологических исследований. Психофармакология и биологическая наркология 2007; 3–4: 2090–2120 / Prozorovskiy V.B. Statistical processing of the results of pharmacological studies. Psikhofarmakologiya i biologicheskaya narkologiya 2007; 3–4: 2090–2120 (in Russian).
Supplementary files
